Investment Rating - The report maintains a "Strong Buy" rating for the company [2] Core Insights - The company reported a revenue of 1.214 billion yuan for the first half of 2025, representing a year-on-year growth of 21.26%, with a net profit of 425 million yuan, up 24.11% year-on-year [1] - The company's core product, PFA, has gained rapid acceptance in major hospitals, with over 800 procedures completed [5] - The vascular intervention business continues to expand, with coronary business revenue reaching 654 million yuan, a year-on-year increase of 30.02% [5] - International business revenue grew by 23.84% year-on-year, with a notable 34.56% increase in key overseas markets [5] - The overall gross margin improved to 73.51%, contributing to a net profit margin increase to 34.51% [5] Financial Performance - The company expects revenues of 2.691 billion yuan, 3.475 billion yuan, and 4.553 billion yuan for 2025, 2026, and 2027 respectively, with growth rates of 30%, 29%, and 31% [6] - The projected net profit for the same years is 900 million yuan, 1.172 billion yuan, and 1.535 billion yuan, with growth rates of 34%, 30%, and 31% [6] - The company's PE ratios for 2025, 2026, and 2027 are projected to be 44, 34, and 26 respectively [6] Key Financial Ratios - The company's gross margin is expected to improve gradually, reaching 73.3% by 2027 [9] - The net profit margin is projected to stabilize around 33.7% by 2027 [9] - The return on equity (ROE) is expected to increase to 31.6% by 2027 [9]